HR 1532

Scientific EXPERT Act of 2025

Congress: 119 (2025–2027, Current)
Chamber: House
Policy Area: Health
Introduced: Feb 24, 2025
Current Status: Referred to the House Committee on Energy and Commerce.
Latest Action: Referred to the House Committee on Energy and Commerce. (Feb 24, 2025)
Official Text: https://www.congress.gov/bill/119th-congress/house-bill/1532

Sponsor

Name: Rep. Matsui, Doris O. [D-CA-7]
Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bilirakis, Gus M. [R-FL-12]	R · FL		Feb 24, 2025
Rep. Tonko, Paul [D-NY-20]	D · NY		Jun 10, 2025

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Feb 24, 2025

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
119 S 822	Related bill	**Mar 3, 2025:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Feb 24, 2025)

Scientific External Process for Educated Review of Therapeutics Act of 2025 or the Scientific EXPERT Act of 2025

This bill requires the Food and Drug Administration (FDA) to facilitate and participate in externally led, science-focused drug development meetings to discuss the development of treatments for rare diseases and conditions.

The FDA must enter into an arrangement with the Reagan-Udall Foundation for the FDA under which the foundation agrees to convene such meetings. Meetings must be held at least four times a year, and each meeting must focus on a different rare disease or condition.

The foundation must establish a permanent steering committee to review and recommend topics for each meeting. In evaluating potential topics, the committee must consider unmet therapeutic needs, patient population sizes for different diseases and conditions, and whether a disease or condition would benefit from clarity and alignment on drug development questions, among other factors.

In planning each meeting, the foundation must develop a list of medical experts, drug sponsors, scientific organizations, patient organizations, and other entities to be invited to participate. Representatives of the FDA's review divisions must attend each meeting.

After each meeting, the foundation must make available a summary of the meeting noting areas of consensus, areas where additional clarification or information is needed, and next steps agreed upon with the FDA.

The bill also requires the FDA to indicate whether it incorporated any input from these meetings when approving a new drug or biologic.

Actions Timeline

- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House

Feb 24, 2025: Referred to the House Committee on Energy and Commerce.

- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.
- **Feb 24, 2025:** Introduced in House
- **Feb 24, 2025:** Referred to the House Committee on Energy and Commerce.